Convergence of Genetic, Nutritional and Inflammatory Factors in Gastrointestinal Cancers

Nutrition Reviews

Volumn 65, Issue SUPPL.3, 2007, Pages

  Macfarlane, Amanda J ^a   Stover, Patrick J ^a  

^a Department of Obstetrics Gynecology   (United States)

Author keywords

Cancer; Celiac disease; Gastrointestinal; Helicobacter pylori; Inflammation; Irritable bowel disease

Indexed keywords

CYCLOOXYGENASE 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN;

DIET; ENTEROPATHY; GASTROINTESTINAL TUMOR; GENE EXPRESSION REGULATION; GENETIC VARIABILITY; GENETICS; HUMAN; INFLAMMATION; METABOLISM; REVIEW;

CYCLOOXYGENASE 2; DIET; GASTROINTESTINAL NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INFLAMMATION; INTESTINAL DISEASES; NF-KAPPA B; VARIATION (GENETICS);

EID: 39649115215     PISSN: 00296643     EISSN: 17534887     Source Type: Journal    
DOI: 10.1111/j.1753-4887.2007.tb00355.x     Document Type: Article

References (83)

1. Cancer Trends Progress Report-2005 Update, National Cancer Institute, NIH, DHHS, Bethesda, MD, December 2005. Available at: http:progressreport-.cancer.gov. Accessed April 10, 2007.
2. Ries LAG, Eisner MP, Kosary CL, et al., eds. SEER Cancer Statistics Review, 1975-2002, National Cancer Institute. Bethesda, MD. Available at: http:seer.cancer.govcsr1975_2002. Accessed April 10, 2007.
3. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 1997;349:1498-1504.
4. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin 2006;56:106-130.
5. Gunter MJ, Stolzenberg-Solomon R, Cross AJ, et al. A prospective study of serum C-reactive protein and colorectal cancer risk in men. Cancer Res 2006;66:2483-2487.
6. Nardone G, Rocco A, Malfertheiner P. Review article: Helicobacter pylori and molecular events in precancerous gastric lesions. Aliment Pharmacol Ther 2004;20:261-270.
7. Reya T, Clevers H. Wnt signalling in stem cells and cancer. Nature 2005;434:843-850.
8. Ma J, Stampfer MJ, Giovannucci E, et al. Methyl-enetetrahydrofolate reductase polymorphism, dietary interactions, and risk of colorectal cancer. Cancer Res 1997;57:1098-1102.
9. Guarner F. Enteric flora in health and disease. Digestion 2006;73(suppl):5-12.
10. Walker WA. Role of the mucosal barrier in toxin/ microbial attachment to the gastrointestinal tract. Ciba Found Symp 1985;112:34-56.
11. Radtke F, Clevers H, Riccio O. From gut homeosta-sis to cancer. Curr Mol Med 2006;6:275-289.
12. Ayabe T, Ashida T, Kohgo Y, Kono T. The role of Paneth cells and their antimicrobial peptides in innate host defense. Trends Microbiol 2004;12:394-398.
13. Uhlig HH, Powrie F. Dendritic cells and the intestinal bacterial flora: a role for localized mucosal immune responses. J Clin Invest 2003;112:648-651.
14. Mowat AM, Millington OR, Chirdo FG. Anatomical and cellular basis of immunity and tolerance in the intestine. J Pediatr Gastroenterol Nutr 2004;39(suppl):723-724.
15. Iwasaki A, Kelsall BL Mucosal immunity and inflammation. I. Mucosal dendritic cells: their specialized role in initiating T cell responses. Am J Physiol 1999;276(5 Pt 1): G1074-1078.
16. Mowat AM. Anatomical basis of tolerance and immunity to intestinal antigens. Nat Rev Immunol 2003;3:331-341.
17. van Horssen R, Ten Hagen TL, Eggermont AM. TNF-alpha in cancer treatment: molecular insights, antitumor effects, and clinical utility. Oncologist 2006;11:397-408.
18. Szlosarek P, Charles KA, Balkwill FR. Tumour necrosis factor-alpha as a tumour promoter. Eur J Cancer 2006;42:745-750.
19. Karin M. NF-kappaB and cancer: mechanisms and targets. Mol Carcinog 2006;45:355-361.
20. Schottelius AJ, Dinter H. Cytokines, NF-kappaB, microenvironment, intestinal inflammation and cancer. Cancer Treat Res 2006;130:67-87.
21. Rose-John S, Scheller J, Elson G, Jones SA. Inter-leukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer. J Leukoc Biol 2006;80:227-236.
22. Scheller J, Ohnesorge N, Rose-John S. Interleu-kin-6 trans-signalling in chronic inflammation and cancer. Scand J Immunol 2006;63:321-329.
23. Kusters JG, van Vliet AH, Kuipers EJ. Pathogenesis of Helicobacter pylori infection. Clin Microbiol Rev 2006;19:449-490.
24. Correa P. Helicobacter pylori and gastric carcino-genesis. Am J Surg Pathol 1995;(suppl):37-43.
25. Correa P. Human gastric carcinogenesis: a multi-step and multifactorial process-First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res 1992;52:6735-6740.
26. Graham DY, Go MF. Helicobacter pylori: current status. Gastroenterology 1993;105:279-282.
27. Danesh J. Helicobacter pylori infection and gastric cancer: systematic review of the epidemiological studies. Aliment Pharmacol Ther 1999;13:851-856.
28. Marshall BJ, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet 1984;1:1311-1315.
29. An international association between Helicobacter pylori infection and gastric cancer. The EUROGAST Study Group. Lancet 1993;341:1359-1362.
30. Huang JQ, Sridhar S, Chen Y, Hunt RH. Meta-analysis of the relationship between Helicobacter pylori seropositivity and gastric cancer. Gastroenterology 1998;114:1169-1179.
31. Eslick GD, Lim LL, Byles JE, Xia HH, Talley NJ. Association of Helicobacter pylori infection with gastric carcinoma: a meta-analysis. Am J Gastroenterol 1999;94:2373-2379.
32. Helicobacter and Cancer Collaborative Group. Gastric cancer and Helicobacter pylori: a combined analysis of 12 case control studies nested within prospective cohorts. Gut 2001;49:347-353.
33. Uemura N, Okamoto S, Yamamoto S, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001;345:784-789.
34. Brenner H, Arndt V, Stegmaier C, Ziegler H, Rothen-bacher D. Is Helicobacter pylori infection a necessary condition for noncardia gastric cancer Am J Epidemiol 2004;159:252-258.
35. Ernst PB, Peura DA, Crowe SE. The translation of Helicobacter pylori basic research to patient care. Gastroenterology 2006;130: 188-206; quiz 212-183.
36. Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN. Up-regulation of cyclo-oxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994;107:1183-1188.
37. Sinicrope FA. Targeting cyclooxygenase-2 for prevention and therapy of colorectal cancer. Mol Carcinog 2006;45:447-454.
38. Wallace JL. COX-2: a pivotal enzyme in mucosal protection and resolution of inflammation. Sci World J 2006;6:577-588.
39. Dubois RN, Abramson SB, Crofford L, et al. Cyclo-oxygenase in biology and disease. Faseb J 1998;12:1063-1073.
40. Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998;93:705-716.
41. Lupulescu A. Enhancement of carcinogenesis by prostaglandins. Nature 1978;272:634-636.
42. Potter JD, Ulrich CM. COX-2 and gastric cancer: more on inflammation and neoplasia. Gastroenter-ology 2006;130:2198-2200.
43. Ricchi P, Zarrilli R, Di Palma A, Acquaviva AM. Nonsteroidal anti-inflammatory drugs in colorectal cancer: from prevention to therapy. Br J Cancer 2003;88:803-807.
44. Ji KY, Hu FL Interaction or relationship between Helicobacter pylori and non-steroidal anti-inflammatory drugs in upper gastrointestinal diseases. World J Gastroenterol 2006;12:3789-3792.
45. National Institutes of Health. Consensus Development Conference Statement. June 28-30, 2004. Available at: http:consensus.nih.gov20042004CeliacDisease118html.htm. Accessed October 22, 2007.
46. Catassi C, Bearzi I, Holmes GK. Association of celiac disease and intestinal lymphomas and other cancers. Gastroenterology 2005;128(suppl):79-86.
47. Dewar DH, Ciclitira PJ. Clinical features and diagnosis of celiac disease. Gastroenterology 2005;128(suppl):19-24.
48. Zanoni G, Navone R, Lunardi C, et al. In celiac disease, a subset of autoantibodies against trans-glutaminase binds toll-like receptor 4 and induces activation of monocytes. PLoS Med 2006;3:e358.
49. Diosdado B, van Oort E, Wijmenga C. Coelionom-ics": towards understanding the molecular pathology of coeliac disease. Clin Chem Lab Med 2005;43:685-695.
50. Koning F. Celiac disease: caught between a rock and a hard place. Gastroenterology 2005;129:1294-1301.
51. Go JH. Methylation analysis of cyclin-dependent kinase inhibitor genes in primary gastrointestinal lymphomas. Mod Pathol 2003;16:752-755.
52. Jess T, Gamborg M, Matzen P, Munkholm P, So-rensen TI. Increased risk of intestinal cancer in Crohn's disease: a meta-analysis of population-based cohort studies. Am J Gastroenterol 2005;100:2724-2729.
53. Loftus EV, Jr. Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences. Gastroenterology 2004;126:1504-1517.
54. Itzkowitz SH, Harpaz N. Diagnosis and management of dysplasia in patients with inflammatory bowel diseases. Gastroenterology 2004;126:1634-1648.
55. Itzkowitz SH, Yio X. Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation. Am J Physiol Gastrointest Liver Physiol 2004;287: G7-17.
56. Linskens RK, Huijsdens XW, Savelkoul PH, Vanden-broucke-Grauls CM, Meuwissen SG. The bacterial flora in inflammatory bowel disease: current insights in pathogenesis and the influence of antibiotics and probiotics. Scand J Gastroenterol Suppl 2001:29-40.
57. Risques RA, Rabinovitch PS, Brentnall TA. Cancer surveillance in inflammatory bowel disease: new molecular approaches. Curr Opin Gastroenterol 2006;22:382-390.
58. Erlinger TP, Platz EA, Rifai N, Helzlsouer KJ. C-re-active protein and the risk of incident colorectal cancer. JAMA 2004;291:585-590.
59. Benamouzig R, Deyra J, Martin A, et al. Daily soluble aspirin and prevention of colorectal adenoma recurrence: one-year results of the APACC trial. Gastroenterology 2003;125:328-336.
60. Sandler RS, Halabi S, Baron JA, et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 2003;348:883-890.
61. Giardiello FM, Hamilton SR, Krush AJ, et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 1993;328:1313-1316.
62. Nugent KP, Farmer KC, Spigelman AD, Williams CB, Phillips RK. Randomized controlled trial of the effect of sulindac on duodenal and rectal polyposis and cell proliferation in patients with familial adenomatous polyposis. Br J Surg 1993;80:1618-1619.
63. Labayle D, Fischer D, Vielh P, et al. Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology 1991;101:635-639.
64. Giardiello FM, Yang VW, Hylind LM, et al. Primary chemoprevention of familial adenomatous polyposis with sulindac. N Engl J Med 2002;346:1054-1059.
65. Ladenheim J, Garcia G, Titzer D, et al. Effect of sulindac on sporadic colonic polyps. Gastroenterology 1995;108:1083-1087.
66. Steinbach G, Lynch PM, Phillips RK, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000;342:1946-1952.
67. Higuchi T, Iwama T, Yoshinaga K, Toyooka M, Ta-keto MM, Sugihara K. A randomized, double-blind, placebo-controlled trial of the effects of rofecoxib, a selective cyclooxygenase-2 inhibitor, on rectal polyps in familial adenomatous polyposis patients. Clin Cancer Res 2003;9:4756-4760.
68. Grosch S, Maier TJ, Schiffmann S, Geisslinger G. Cyclooxygenase-2 (COX-2)-independent anticarci-nogenic effects of selective COX-2 inhibitors. J Natl Cancer Inst 2006;98:736-747.
69. Mann JR, Backlund MG, DuBois RN. Mechanisms of disease: inflammatory mediators and cancer prevention. Nat Clin Pract Oncol 2005;2:202-210.
70. Brown JR, DuBois RN. COX-2: a molecular target for colorectal cancer prevention. J Clin Oncol 2005;23:2840-2855.
71. Couzin J. Drug safety. Withdrawal of Vioxx casts a shadow over COX-2 inhibitors. Science 2004;306:384-385.
72. Nishimoto N. Clinical studies in patients with Castleman's disease, Crohn's disease, and rheumatoid arthritis in Japan. Clin Rev Allergy Immunol 2005;28:221-230.
73. Feagan BG, Sandborn WJ, Baker JP, et al. A randomized, double-blind, placebo-controlled trial of CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, in patients with cortico-steroid-dependent Crohn's disease. Aliment Pharmacol Ther 2005;21:373-384.
74. Tlaskalova-Hogenova H, Stepankova R, Hudcovic T, et al. Commensal bacteria (normal microflora), mucosal immunity and chronic inflammatory and autoimmune diseases. Immunol Lett 2004;93:97-108.
75. Slattery ML, Sweeney C, Murtaugh M, et al. Associations between vitamin D, vitamin D receptor gene and the androgen receptor gene with colon and rectal cancer. Int J Cancer 2006;118:3140-3146.
76. Garland CF, Garland FC, Gorham ED, et al. The role of vitamin D in cancer prevention. Am J Public Health 2006;96:252-261.
77. Holick MF. Vitamin D: its role in cancer prevention and treatment. Prog Biophys Mol Biol 2006;92:49-59.
78. Nelson MA, Goulet AC, Jacobs ET, Lance P. Studies into the anticancer effects of selenomethionine against human colon cancer. Ann NY Acad Sci 2005;1059:26-32.
79. Stover PJ. Physiology of folate and vitamin B12 in health and disease. Nutr Rev 2004;62(suppl): 3-12; discussion 13.
80. Eichholzer M, Luthy J, Moser U, Fowler B. Folate and the risk of colorectal, breast and cervix cancer: the epidemiological evidence. Swiss Med Wkly 2001;131:539-549.
81. Friso S, Choi SW, Girelli D, et al. A common mutation in the 5, 10-methylenetetrahydrofolate reduc-tase gene affects genomic DNA methylation through an interaction with folate status. Proc Natl Acad Sci USA 2002;99:5606-5611.
82. Chen J, Giovannucci E, Kelsey K, et al. A methyl-enetetrahydrofolate reductase polymorphism and the risk of colorectal cancer. Cancer Res 1996;56:4862-4864.
83. Kim YI. Folate and colorectal cancer: an evidence-based critical review. Mol Nutr Food Res 2007;51:267-292.